United States Health

CareTrust REIT (NYSE:CTRE) agreed to acquire 45 U.K. care homes from LNT for about £1.1 billion, including 24 properties acquired for approximately £576 million in the first closing.

Cullinan Therapeutics (NASDAQ:CGEM) initiated an FDA New Drug Application for first-line zipalertinib plus chemotherapy after REZILIENT3 showed a 6.0-month median progression-free survival improvement.

Ultragenyx (NASDAQ:RARE) announced that the European Medicines Agency validated its marketing authorisation application for investigational gene therapy rebisufligene etisparvovec to treat Sanfilippo syndrome Type A.

Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration with AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway in multiple solid tumor settings, including breast and lung cancer.

Shares of major U.S. health insurers moved lower after companies including UnitedHealth Group (NYSE:UNH) and CVS Health (NYSE:CVS) subsidiary Aetna announced their Medicare Advantage plan designs for 2027.

PolyPid (NASDAQ:PYPD) regained exclusive European commercialization rights for D-PLEX₁₀₀ after the company and ADVANZ PHARMA mutually agreed to terminate their 2022 licensing, distribution and supply agreement covering Europe.

Novo Nordisk (NYSE:NVO) presented exploratory analyses from the STEP UP program showing that Wegovy (semaglutide) was associated with reductions in liver fat among adults with obesity who did not have diabetes.

Cardinal Health (NYSE:CAH) entered into a binding letter of intent with CVS Health to extend their existing pharmaceutical distribution agreement through June 30, 2032.

Agomab (NASDAQ:AGMB) reported topline results from the STENOVA open-label extension study of ontunisertib in patients with fibrostenosing Crohn’s disease, with 49 patients completing the 48-week extension period.

Shattuck Labs (NASDAQ:STTK) announced plans to evaluate SL-325 in a Phase 2 clinical trial for patients with moderate to severe hidradenitis suppurativa (HS), expanding the program beyond its existing inflammatory bowel disease development.

Eli Lilly (NYSE:LLY) reported post-hoc analyses from the Phase 3 ATTAIN-1 trial showing Foundayo was associated with lower modeled 10-year risks of type 2 diabetes and cardiovascular disease in adults with obesity or overweight.

United Therapeutics (NASDAQ:UTHR) announced that a Delaware federal court found Liquidia’s Yutrepia infringes two claims of a patent covering inhaled treprostinil treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).